Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients

Ain Shams University

Status

Completed

Conditions

Sodium Glucose Co-Transporter 2 Inhibitors

Chronic Kidney Disease

Diabetes

Estimated Glomerular Filtration Rate

Treatments

Other: Sodium Glucose Co-Transporter 2 Inhibitors

Study type

Observational

Funder types

Other

Identifiers

NCT07302464

FMASU MS 603/2024

Details and patient eligibility

About

The work aimed to compare the effects of Sodium-glucose co-transporter-2 (SGLT2) inhibitors on glomerular filtration rate (GFR) in patients with diabetic chronic kidney disease (CKD) and non-diabetic CKD.

Full description

Glucose reabsorption is mediated by the sodium-glucose cotransporter (SGLT) 2, which reabsorbs 90% of glucose, and SGLT1, which reabsorbs the remaining 10%.

The relationship between hyperglycaemia and the development of renal disease is complex. Hyperglycaemia-induced complications are mediated by several metabolic pathways, among which accumulation of Advanced Glycation End-products with abnormalities of the glycosylation of macromolecules and increased glucose flux through the polyol pathway seem to be the most important.

Enrollment

60 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥ 18 years.
Both sexes.
Chronic kidney disease (CKD) participants with stages 3 and 4.

Exclusion criteria

Patients with type 1 diabetes mellitus (DM).
Patients with decompensated Chronic liver disease.
Patients with uncontrolled hypertension.
Patients with blood pressure (BP) > 110/70.
Patients already on the same medication (Sodium Glucose Co-Transporter 2 Inhibitors).
Patients with a history of recurrent or recent urinary tract infection (UTI).
Patients with glycated hemoglobin (HbA1c) ≤10.
Adult polycystic kidney disease.
All patients on immunosuppressive medications.